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Abstract
The aim of this study was to examine the bone augmentation properties of an injectable composite
consisting of PLGA microspheres/CaP cement (20/80), and the additional effect of loading
PLGA microspheres with TGF-β1 (200 ng). For this purpose, PLGA/CaP composites (control) and
PLGA/CaP composites loaded with TGF-β1 (test group) were injected on top of the skulls of 24
Wistar rats. Each rat received 2 materials from the same experimental group, and in total 48
implants were placed (n = 8). After 2, 4, and 8 weeks the results were evaluated histologically
and histomorphometrically. The contact length between the implants and newly formed bone
increased in time, and was significantly higher for the TGF-β1-loaded composites after 2 weeks.
Also, bone formation was significantly higher for the TGF-β1-loaded composites (18.5% ± 3)
compared to controls (7.21% ± 5) after 8 weeks of implantation. Immunohistochemical staining
demonstrated massive inflammatory infiltrates in both groups, particularly at 2 weeks, which
decreased substantially at 4 and 8 weeks. In conclusion, injectable PLGA/CaP composites stimulated
bone augmentation in a rat model. The addition of TGF-β1 to the composite significantly increased
bone contact at 2 weeks and enhanced new bone formation at 8 weeks. Copyright  2008 John
Wiley & Sons, Ltd.
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1. Introduction
Autogenous bone is still considered to be the ‘gold
standard’ for bone augmentation. However, due to
the known limitations of autogenous bone grafting,
such as donor site morbidity and limited supply,
increasing efforts focus on the development of bone
substitutes. In order to create a bone graft, which
is comparable or superior to bone, allografts are
combined with osteoinductive substances, such as growth
factors. Transforming growth factor-β1 (TGF-β1) is
a member of TGF-β superfamily, which regulates
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key aspects in bone metabolism (Massague´, 1990).
It affects osteoblast differentiation, matrix formation
and mineralization. Furthermore, it exerts its functions
both during embryogenesis and in adult organisms,
orchestrating complex phenomena such as inflammation
and tissue repair (Roberts and Sporn, 1993). Studies
have shown that TGF-β1 supplied to a variety of
biomaterials is able to enhance bone formation in vivo,
depending on concentration and application method
(Okuda et al., 1995; Sumner et al., 1995; Lind et al.,
1996). Consequently, TGF-β1 is an appealing factor for
use in clinical procedures for bone augmentation.
As mentioned above, various materials have already
been used for local delivery of TGF-β1, including
calcium phosphate (CaP) ceramics (Okuda et al., 1995;
Sumner et al., 1995; Lind et al., 1996). This material has
been selected for bone replacement and augmentation,
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due to its excellent bone behaviour. The shortcomings
of the prefabricated CaP ceramics, such as lack of
shaping and difficult delivery to the defects, have been
overcome by the development of injectable CaP cements
(Ooms et al., 2005). Injectable self-setting cement can
fill macroscopic as well as microscopic bone defects.
Cements of this kind may be resorbed, allowing gradual
replacement by host bone (Jansen et al., 1995). To
promote degradation and tissue ingrowth injectable CaP
cements have been combined with PLGA microspheres
(Ruhe et al., 2003). Additionally, these degradable PLGA
microspheres provide a method for delivery of bone
formation promoting proteins, such as TGF-β1. Such an
injectable composite has been developed by our group
and comprehensively studied in vitro and in vivo (Ruhe
et al., 2003, 2005, 2007). However, the direct mode of
application in a bone augmentation model has not yet
been evaluated.
In view of the above-mentioned, the aim of this study
was to examine the bone augmentation properties of
an injectable PLGA–CaP composite and to evaluate the
additional effect of loading the composite with TGF-β1 in
a rat model.
2. Materials and Methods
2.1. Materials
The calcium phosphate cement Calcibon (Biomet Merck,
Darmstadt, Germany) was used in this study. The cement
powder consisted of 62.5% α-tri-calcium phosphate (α-
TCP), 26.8% CaHPO4, 8.9% CaCO3 and 1.8% precipitated
hydroxyapatite (PHA). An aqueous solution of 1%
Na2HPO4 was used as a liquid component with a
liquid : powder ratio of 0.35 ml/g. Low-molecular weight
poly(DL-lactic-co-glycolic acid) (PLGA) Purasorb was
provided by Purac (Gorinchem, The Netherlands). Human
rh-TGF-β1 was supplied by R&D Systems (Abingdon, UK).
2.2. Preparation of PLGA microspheres
PLGA microspheres were prepared using a water-in-oil-
in-water (w/o/w)-double emulsion solvent evaporation
technique, as described previously by Ruhe et al. (2003).
Briefly, 1.4 g low molecular weight (LMW) PLGA was
dissolved in 2 ml dichloromethane (DCM) inside a 50 ml
polypropylene (PP) tube; 500 µl demineralized water
(ddH2O) was added while vortexing vigorously for 1 min,
subsequently adding 6 ml 0.3% polyvinylalcohol (PVA)
solution. Vortexing was continued for another 1 min. The
content of the 50 ml tube was transferred to a stirred
1000 ml beaker and another 394 ml 0.3% PVA was added
slowly. This was directly followed by adding 400 ml 2%
isopropylic alcohol (IPA) solution. The suspension was
stirred for 1 h. The spheres were allowed to settle for
15 min and the solution was decanted. The suspension
left was centrifuged and the clear solution at the top
was decanted. ddH2O (5.0 ml) was added, the spheres
were washed, centrifuged and the solution was aspirated.
Finally, the spheres were frozen, freeze-dried for 24 h and
stored under argon at −20 ◦C.
2.3. Adsorption of TGF-β1 on PLGAmicrospheres
Recombinant human TGF-β1 (rh-TGF-β1; 1 µg) was
dissolved in 800 µl 0.1% acetic acid and added to
1.0 g microspheres, after which the TGF-β1 was freeze-
dried onto the microspheres. The entrapment efficiency
of the protein was determined by normalizing the
amount actually entrapped with the amount added to
the fabrication process.
2.4. Preparation of PLGA–CaP composites
Composites were made by adding PLGA microspheres to
the CaP cement in a PLGA : CaP cement weight ratio
of 20 : 80. The cement powder was sterilized by γ -
irradiation of 25 kGy (Isotron B.V., Ede, The Netherlands)
and the cement liquid was filter-sterilized (0.2 µm
filter). First, 256 mg CaP cement powder provided
with 64 mg PLGA microspheres was added to a 2 ml
plastic syringe (Sherwood Medical Monojet, Schwallbach,
Germany). The mixture was shaken vigorously for 15 s,
using a Silamat mixing apparatus (Vivadent, Schaan,
Liechtenstein). Subsequently, 125 mg 1% Na2HPO4
was applied to the mixture, shaken again for 15 s
and then delivered by means of the syringe to the
surgical site. PLGA–CaP composites provided with TGF-
β1 were made by adding a fraction of TGF-β1-adsorbed
PLGA microspheres to a fraction of as-prepared PLGA
microspheres, followed by the same procedure as
described for the unloaded composites. The average
amount of delivered material was 60 mg and the growth
factor-loaded composites contained 200 ng TGF-β1.
2.5. Surgical procedure
For the animal experiment, 24 healthy, skeletally mature
male Wistar rats, with an average weight of 250 g, were
used. National guidelines for care and use of laboratory
animals were observed, and the Animal Ethical Committee
of the Radboud University Nijmegen Medical Centre
approved the study protocol. In total, 48 composite
implants were placed; each animal received two implants
from the same group on its parietal cranial bone for
evaluation periods of 2, 4 and 8 weeks (n = 8 for each
material and evaluation time).
Anaesthesia was induced with 4% Isoflurane by a non-
rebreather mask and maintained with 2% Isoflurane,
0.4% N2O and 0.4% O2 during surgery. The animals
were premedicated by an intramuscular injection of
fentanyl (2.7 ml/kg) to reduce the operative pain, and
a subcutaneous injection of buprenorphine (150 µg/kg)
was applied to reduce the postoperative pain.
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Figure 1. Rat model for bone augmentation. (A) Defect; (B) silicon mould; (C) PLGA–CaP composite in mould; (D) PLGA–CaP
composite after setting and removal of the mould
Before surgery, the rat cranium was shaved and
swabbed with iodine. A medial sagittal incision extending
from the nasofrontal area to the occipital protuberance
was made and soft tissues were sharp dissected to
visualize the cranial periosteum. Subsequently, the
periosteum was undermined and reflected, exposing the
parietal bones. A hollow trephine bur (ACE Dental Implant
System, Brockton, MA, USA) with an outer diameter of
5 mm in a dental handpiece was used to mark the position
of two augmentation sites on the parietal bone, aside from
the sagittal sinus. The trephine burr did not penetrate into
the whole thickness of the skull, but was stopped just in
the upper part of the cortical plate, next to the periosteum.
Within the marked areas, the cranial surface was scratched
in order to remove part of the cortical bone and to achieve
exposure of the osteogenic cells. Afterwards, a silicon
mould with a diameter of 5 mm, specifically designed
for this purpose, was placed on the cranium and the
PLGA–CaP composite was injected (Figure 1). In this way,
implants in the form of discs were created, with a diameter
of 5 mm and a height of 2 mm. After setting of the
composite, the mould was removed and the periosteum
and overlying skin were closed in separate layers with 5-0
and 4-0 Vicryl resorbable sutures, respectively.
2.6. Histological preparation
The animals were sacrificed 2, 4, and 8 weeks after
surgery, using an overdose of carbon dioxide. The
skin was dissected and the defect sites were removed,
along with the surrounding bone and soft tissues, and
fixed in 10% neutral formalin for 1 week. Half of the
specimens (n = 4 per material and evaluation time) were
dehydrated in gradual series of alcohol and embedded in
polymethylmethacrylate (PMMA). Before the embedding
procedure, samples were cut exactly through the middle
of the implants to ensure that the microtome sections
were made in the area of interest and the same region
was analysed for each sample. After polymerization,
sections were prepared using a modified diamond-blade
sawing microtome technique (Leica Microsystems GmbH,
Wetzlar, Germany). The sections were approximately
10 µm thick and were stained with methylene blue
and basic fuchsin. The remaining specimens (n = 4 per
material and implantation time) were decalcified for
2 weeks in Formical-2000 (Immunodiagnostika & Biotech
GmbH, Berlin, Germany) and then embedded in Paraplast
paraffin (Klinipath B.V., Duiven, the Netherlands).
Sagittal microtome sections were made, 5 µm in thickness,
which were stained with haematoxylin and eosin (H&E)
and immunohistochemically using an antibody against
CD68 (Macrosialin; Janeway et al., 1999) to detect
inflammatory cells, including monocytes, macrophages
and neutrophils. Again, before the embedding procedure,
samples were cut exactly through the middle of the
implants.
The light microscopical evaluation of all sections was
done using an optical microscope (Leica BW, Rijswijk, The
Netherlands), and consisted of a complete morphological
description of the tissue response to different implants as
well as of histomorphometrical analysis.
2.7. Histomorphometry
For the histomorphometrical analysis, a Leica Qwin
Proimage analysis system (Leica BV, Rijswijk, The
Netherlands) was used. Sections were digitized at low
magnification (×2.5) and measurements were done on
three sections per cranial specimen. All PMMA sections
were used for evaluation of bone response and all paraffin
sections for assessment of inflammatory reaction.
To quantify the amount of bone augmentation, newly
formed bone, as stained and discerned by its woven
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structure and location, was marked manually and its area
was measured. Afterwards, this ROI was subtracted from
the whole area of the implant. From these two data, the
amount of bone formation (%) was calculated.
In order to measure the contact length between the
implants and the bone, lines were drawn manually at the
direct interface between the composites and newly formed
bone. The sum of these intersections was calculated and
interpreted as contact bone–composite length.
Further, the intensity of the inflammatory response
around the implants was quantified. For this purpose,
pictures with higher magnification (i.e. ×10) were used.
The presence of macrophages was detected with anti-
CD68 staining and subsequently digitized by a computer
program in the region of interest (implant + surrounding
tissue; ROI). The areas with positive anti-CD68 staining
were given as a percentage (%) of the total ROI.
2.8. Statistical analysis
For the statistical analyses, the GraphPad InStat program
(GraphPad Software, San Diego, CA, USA) was used.
One-way analysis of variance (ANOVA) was performed on
the data obtained from the histomorphometric analyses.
ANOVA assumes that the data are sampled from popula-
tions with identical standard deviations. This assumption
was tested using the method of Bartlett. Further, ANOVA
assumes that the data are sampled from populations that
follow Gaussian distributions. This assumption was tested
using the Kolmogorov–Smirnov method. In addition, a
Tukey–Kramer multiple comparisons test was done. Dif-
ferences were considered to be significant when p < 0.05.
3. Results
3.1. General observations
The injection of the composite into the silicon mould
placed on the scratched cranial surface went without
complications. The setting time of both loaded and
unloaded composites was about 10 min. Setting and
handling properties of the composites were influenced
by the presence of blood. When the composite was
injected on dry, good isolated cranial surfaces the setting
time was shorter, the composite was easily shaped, and
after removal of the mould the implant was secured
more stable. Mixing with blood affected the handling
properties of the composites and made them more
fragile. In addition, the composites loaded with TGF-
β1 appeared to be more fragile after setting than the
unloaded composites, as indicated by easy cracking.
During the implantation periods, all animals remained
in good health. At sacrifice, macroscopic signs of
inflammation and adverse reaction were apparent around
loaded as well as unloaded implants, predominantly after
2 and 4 weeks. After 8 weeks, the signs of inflammation
disappeared. Upon retrieval, all implants in both groups
were in situ and surrounded by a fibrous capsule. The
capsule thickness differed between different time points,
with a tendency to reduction for the later periods. No
differences between the loaded and unloaded composites
were observed.
3.2. Descriptive histology
Histological examination of PMMA-embedded samples
revealed new bone formation in both groups at all time
points. Newly formed bone was more abundant at 4
and 8 weeks than at 2 weeks (Figure 2). Bone formation
was observed at the defect margins and along the lower
part of the cement at the side of the cranium. No
bone formation was seen from the periosteum side on
the top of the implants, or throughout the implant.
At higher magnification, newly formed bone revealed
thin trabeculae and large marrow spaces filled with fat
tissue and haematopoietic cells. In addition, a direct
contact between the composites and newly formed bone,
without any fibrous tissue interface, was apparent in both
experimental and control groups (Figure 3). Furthermore,
Figure 2. Light micrographs of PMMA-embedded specimens showing bone augmentation at different time points (×2.5
magnification)
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implants managed to stay in place during all investigation
periods. However, the integrity of the composite structure
appeared to be affected. Fractures, as observed inside the
implants, were filled with fibrous tissue and inflammatory
cells. Signs of inflammation were best visible in paraffin
sections stained for CD68. The inflammatory infiltrate,
consisting of macrophages and lymphocytes, surrounded
the implants and penetrated into the composite structure.
In the course of time, a substantial decrease in the
inflammatory response was observed in both groups
(Figure 4). Together with the decrease in inflammation,
a consolidation of the implant fragments and their
incorporation in the bone tissue was noticed. Paraffin
sections stained with H&E did not provide any information
additional to that provided by the PMMA sections.
3.3. Histomorphometry
The amount of newly formed bone was almost the same
for both experimental and control groups after 2 and
4 weeks. At 8 weeks, there was more bone formation in
the group of TGF-β1 loaded implants (18.5 ± 3%) than
in the group of the unloaded ones (7.2 ± 5%), which was
statistically significant (p < 0.05; Figure 5).
The contact length between the composites and newly
formed bone increased with time. At 2 weeks TGF-β1
loaded samples showed significantly better bone contact
than unloaded controls (19 ± 7 mm vs. 2.7 ± 4 mm; p <
0.05). After 4 and 8 weeks, no difference in the contact
length was observed between the groups (Figure 6).
The amount of inflammation after 2 weeks was
substantial for both groups. However, after 4 weeks it
decreased to 9.0 ± 2% for the TGF-β1-loaded implants
and to 13.3 ± 2% for the controls. This difference
between the groups appeared to be statistically significant
(p < 0.01). At 8 weeks, minor inflammation was observed
in both groups (Figure 7).
Figure 3. Histological section of PMMA embedded speci-
men (×10 magnification). (A) unloaded PLGA–CaP composite;
(B) TGF-β1 loaded PLGA–CaP composite. Guided bone forma-
tion is visible with direct contact composite–newly formed bone
without any fibrous tissue interface. Dashed line in yellow indi-
cates the transition between the newly formed bone and the old
bone. OB, old bone; NB, newly formed bone; C, composite
Figure 4. Light micrographs of paraffin sections stained for CD68, showing the inflammatory response at different time points
(×2.5 magnification)
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Figure 5. Histomorphometric measurements of bone formation
(%) for all evaluation periods. ∗p < 0.05 (statistically significant)
4. Discussion
The present study demonstrates that the injectable
PLGA–CaP (20 : 80) composite used stimulated bone
augmentation in a rat model. Moreover, the addition of
TGF-β1 to the composite significantly enhanced new bone
formation at 8 weeks when compared to the control (i.e.
unloaded PLGA–CaP composite). The osteopromotive
effect of TGF-β1 has been demonstrated in many studies
(Arnaud et al., 1994; Zhou et al., 1995; Sumner et al.,
1995; Lind et al., 1996; Beck et al., 1991, 1993; Moxham
et al., 1996). However, there are studies that describe the
absence or even an adverse effect of TGF-β1 on bone
formation (Lind et al., 1994; Aspenberg et al., 1996).
Since it is known that follow-up period, as well as
animal species, may play role in this aspect (Janssens
et al., 2005), it was decided to compare the outcomes of
the current study with similar experimental studies. Our
findings corroborate the results of Vuola et al. (2002).
In their rat cranial model, TGF-β1-loaded coral-based
implants enhanced bone regeneration, and the amount
of newly formed bone was also not significantly higher
compared to the controls until the 8th week. The authors
suggested that the influence of TGF-β1 on bone formation
lasted several weeks and diminished with age. In the study
of Vuola et al., 6–8 month-old rats, weighing 550–560 g,
were used. In our study the experimental animals were
younger, yet skeletally mature, and with a weight of
approximately 250 g. Further, the concentration of TGF-
β1 incorporated in our composites (200 ng) was much
lower than that used in the study of Vuola et al. (1, 2 and
25 µg).
The effect of TGF-β1 on bone formation is known to
be dose-dependent; however, it has to do more with an
optimal than with a maximal dose (Beck et al., 1993).
For example, Blom et al. (2001) reported enhanced bone
formation for the same implantation period with very low
concentrations of TGF-β1 (10 and 20 ng) incorporated in
a similar type of CaP cement. In the current experiment,
enhanced bone formation was also observed with a lower
TGF-β1 dose than applied in similar studies (Okuda et al.,
1995; Bosch et al., 1996). Therefore, it can be suggested
that the amount of TGF-β1 needed to exert an effect may
depend on the type of carrier used.
Figure 6. Histomorphometricmeasurements of composite–bone
contact length (mm) for all evaluation periods. ∗p < 0.05
(statistically significant)
Figure 7. Histomorphometric measurements of the amount
of inflammation (%) for all evaluation periods. ∗∗p < 0.01
(statistically significant)
Delivery systems are of great importance when growth
factors (GFs) are utilized to enhance the bone-healing
process (Puolakkainen et al., 1995). In previous studies
(Ruhe et al., 2003, 2005) it was demonstrated that:
(a) PLGA–CaP composite is a suitable carrier for GFs;
and (b) the method of loading GFs on the scaffold
(freeze-drying on top of the PLGA microspheres) does
not affect their osteoinductive properties. However, the
high protein-binding affinity of CaP cement must be taken
into account. Therefore, it can be hypothesized that after
release from the PLGA microspheres TGF-β1 may have
bound to the CaP cement, resulting in a delayed release
from the composite. This might explain why no increase in
bone formation was seen after 4 weeks for TGF-β1-loaded
materials compared to the controls. At the moment, it is
still unclear whether the TGF-β1, as bound to the CaP
cement, has maintained its osteopromotive properties.
We take note that this has to be an issue of investigation.
It has also to be emphasized that the effect of TGF-β1 on
bone formation differs among species. In general, studies
using rodents and primates as experimental models do
not report such favourable outcomes concerning the
osteopromotive ability of TGF-β1 compared to studies
using dogs (Janssens et al., 2005).
In the current study, the release kinetics of the TGF-β1
from the PLGA–CaP composite was not examined. On
the other hand, similar designed PLGA–CaP composites
were recently used in another study for the delivery
of enamel matrix derivate (EMD) (Plachokova et al., in
press). An in vitro assay revealed that after 4 weeks only
60% of EMD was released from these scaffolds, and this
Copyright  2008 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2007; 1: 457–464.
DOI: 10.1002/term
Bone regenerative properties of injectable PGLA–CaP composite with TGF-β1 463
sustained release continued as observed during extended
follow-up periods. In view of this, it can be speculated
that such a release pattern is too slow for TGF-β1 to
support early bone development. Therefore, the TGF-β1-
promoted bone formation after 4 weeks was enhanced
but not statistically significant compared to the control.
Nevertheless, it must be taken into account that EMD and
TGF-β1 are completely different proteins. Additionally,
the EMD release profile was determined in vitro, which
is known to differ from the in vivo situation. In this
regard, in vitro and in vivo TGF-β1 release profiles from
PLGA–CaP composites are necessary to prove the above-
mentioned hypothesis.
Another reason for lack of significant difference in the
amount of newly formed bone between the groups at 2
and 4 weeks could be the material used as a control. The
PLGA–CaP composite material has already demonstrated
excellent bone regenerative capacity in previous rat
studies (Plachokova et al., in press). Therefore, it appears
unlikely that an osteopromotive agent, such as TGF-
β1, can substantially increase its initial effect on bone
formation, especially when applied in such a low
concentration (i.e. 200 ng).
The PLGA–CaP composite material is a fast-setting
type of cement, which still provides sufficient time
for moulding and contouring in order to achieve
precise adjustment to the defect or augmentation site
(Ginebra et al., 1994; Kairoun et al., 1997). The initial
material–bone (material–implant) contact is of utmost
importance for integration of the filler material and
early onset of remodelling. In cases of discontinuity in
the material–bone (material–implant) interface, fibrous
tissue ingrowth between the filler and the bone–implant
interface will delay bone formation and might result
in failure. To estimate the material–bone interface,
bone contact measurements were performed. In the
current study, the bone contact length for the PLGA–CaP
composite increased from 2.76 to 39.63 mm during
8 weeks of implantation. Moreover, TGF-β1 loading
resulted in an additional increase of the initial bone
contact, since this material showed significantly higher
values of contact length at 2 weeks in comparison with
the unloaded material. The reason for this significantly
increased bone contact in favor of TGF-β1 loaded
composites appears to be unknown and will be subject of
a future investigation.
Concerning the material application method in this
study, direct injection of the PLGA–CaP composite
without fixation was chosen due to the close resemblance
of this mode of application to the final clinical approach.
Nevertheless, it should be taken into account that lack
of rigid fixation of the implants to the skull may have
influenced bone formation. Rigid fixation is known
to decrease movement and shear forces on the graft,
thereby improving revascularization and resulting in
earlier bone apposition and improved osteoconduction
(La Trenta et al., 1989; Lin et al., 1990; Phillips and
Rahn, 1990).
Finally, at 2 weeks of implantation, a serious inflamma-
tory response to the PLGA–CaP material was observed.
In view of this, it has to be noted that the mechani-
cal properties of the PLGA–CaP composite are limited.
As a consequence, tight closure of the periosteum and
subcutaneous tissue over the implants may have caused
high pressure, resulting in the occurrence of fractures in
the cement material. These fractures can be associated
with the appearance of small CaP particles. Orthopaedic
implant studies have already highlighted that CaP parti-
cles can induce an inflammatory response (Pioletti et al.,
2000; Shanbhag et al., 1998; Glant and Jacobs, 1994) or
can alter osteoblast functions if their size is <10 µm (Puleo
et al., 1991). As a result, bone formation will be delayed
until the particles are completely resorbed. A study per-
formed on calvarial rat osteoblasts confirmed the adverse
effect of small CaP particles (<10 µm) on bone forma-
tion (Pioletti et al., 2000). In addition to the presence of
small CaP particles, the cement setting and transforma-
tion may have contributed to the observed inflammatory
response. These processes involve phase transformation of
the ceramic with an associated substantial decrease in pH
(in this study approximately 5.5) (Habraken et al., 2006).
The increased acidity around the implant may have been
responsible for the appearance of inflammatory cells. All
these observations are in agreement with the study of
Huse et al. (2004), who also found an extensive inflam-
matory infiltrate into the pores of similar injectable CaP
cement loaded with TGF-β1 in an onlay rat model.
5. Conclusion
In summary, the injectable PLGA–CaP composite stim-
ulated bone augmentation in a rat model. The addition
of TGF-β1 to the composite significantly increased bone
contact at 2 weeks and enhanced new bone formation
at 8 weeks. For clinical application, mechanical proper-
ties of the injectable composite after setting have to be
improved.
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